chartexchange

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

GlobeNewswire Inc. | Oct 27, 2026 8:01 AM EDT

LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager’s investigational gene therapy designed to lower tau production in the brain, and VY7523, the Company’s clinical stage monoclonal antibody directed against the C-terminal region of tau.

Read original article